Sandoz

Pfizer's new Inflectra biosim data puts J&J's Remicade on notice in Crohn's

EMA raises manufacturing questions over Novartis biosimilar production

Novartis building an antibiotics plant in Slovenia

Sandoz head: Enbrel biosimilar Erelzi won't launch before 2018, delayed by legal battle

Patient requests buoy oral meds from Biogen, Novartis in crowded MS market

Supreme Court takes up Amgen, Sandoz's market-defining biosimilars dispute

Supreme Court urged to weigh in on six-month biosimilar delays

Sandoz imports infant treatment from Canada after U.S. shortage arises

Union lawsuits allege price collusion by Novartis, Taro, Wockhardt, others